<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">plos</journal-id>
      <journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id>
      <journal-id journal-id-type="pmc">ploscomp</journal-id>
      <journal-title-group>
        <journal-title>PLoS Computational Biology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1553-734X</issn>
      <issn pub-type="epub">1553-7358</issn>
      <publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">PCOMPBIOL-D-12-01197</article-id>
      <article-id pub-id-type="doi">10.1371/journal.pcbi.1002959</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Biology</subject>
          <subj-group>
            <subject>Population biology</subject>
            <subj-group>
              <subject>Population dynamics</subject>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Theoretical biology</subject>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Medicine</subject>
          <subj-group>
            <subject>Infectious diseases</subject>
            <subj-group>
              <subject>Viral diseases</subject>
              <subj-group>
                <subject>Hepatitis</subject>
                <subj-group>
                  <subject>Hepatitis C</subject>
                </subj-group>
              </subj-group>
            </subj-group>
            <subj-group>
              <subject>Infectious disease modeling</subject>
              <subject>Sexually transmitted diseases</subject>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline">
          <subject>Infectious Diseases</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Analysis of Hepatitis C Virus Decline during Treatment with the Protease Inhibitor Danoprevir Using a Multiscale Model</article-title>
        <alt-title alt-title-type="running-head">HCV Dynamics Under Therapy with Danoprevir</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
          <name name-style="western">
            <surname>Rong</surname>
            <given-names>Libin</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
          <name name-style="western">
            <surname>Guedj</surname>
            <given-names>Jeremie</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
          <name name-style="western">
            <surname>Dahari</surname>
            <given-names>Harel</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff5">
            <sup>5</sup>
          </xref>
          <xref ref-type="aff" rid="aff6">
            <sup>6</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Coffield</surname>
            <given-names>Daniel J.</given-names>
            <suffix>Jr</suffix>
          </name>
          <xref ref-type="aff" rid="aff7">
            <sup>7</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Levi</surname>
            <given-names>Micha</given-names>
          </name>
          <xref ref-type="aff" rid="aff8">
            <sup>8</sup>
          </xref>
          <xref ref-type="fn" rid="fn1">
            <sup>¤</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Smith</surname>
            <given-names>Patrick</given-names>
          </name>
          <xref ref-type="aff" rid="aff8">
            <sup>8</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Perelson</surname>
            <given-names>Alan S.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">
        <label>1</label>
        <addr-line>Department of Mathematics and Statistics and Center for Biomedical Research, Oakland University, Rochester, Michigan, United States of America</addr-line>
      </aff>
      <aff id="aff2">
        <label>2</label>
        <addr-line>Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America</addr-line>
      </aff>
      <aff id="aff3">
        <label>3</label>
        <addr-line>University Paris Diderot, Sorbonne Paris Cite, 75018 Paris, France</addr-line>
      </aff>
      <aff id="aff4">
        <label>4</label>
        <addr-line>INSERM, UMR 738, 75018 Paris, France</addr-line>
      </aff>
      <aff id="aff5">
        <label>5</label>
        <addr-line>Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, United States of America</addr-line>
      </aff>
      <aff id="aff6">
        <label>6</label>
        <addr-line>Department of Medicine, Loyola University Chicago, Chicago, Illinois, United States of America</addr-line>
      </aff>
      <aff id="aff7">
        <label>7</label>
        <addr-line>University of Michigan-Flint, Mathematics Department, Flint, Michigan, United States of America</addr-line>
      </aff>
      <aff id="aff8">
        <label>8</label>
        <addr-line>Clinical Pharmacology, Pharma Research and Early Development, Roche, Nutley, New Jersey, United States of America</addr-line>
      </aff>
      <contrib-group>
        <contrib contrib-type="editor" xlink:type="simple">
          <name name-style="western">
            <surname>Asquith</surname>
            <given-names>Becca</given-names>
          </name>
          <role>Editor</role>
          <xref ref-type="aff" rid="edit1"/>
        </contrib>
      </contrib-group>
      <aff id="edit1">
        <addr-line>Imperial College London, United Kingdom</addr-line>
      </aff>
      <author-notes>
        <corresp id="cor1">* E-mail: <email xlink:type="simple">asp@lanl.gov</email></corresp>
        <fn fn-type="conflict">
          <p>The authors have declared that no competing interests exist.</p>
        </fn>
        <fn fn-type="con">
          <p>Conceived and designed the experiments: LR JG HD ASP. Performed the experiments: LR JG HD ASP. Analyzed the data: LR JG HD ASP. Contributed reagents/materials/analysis tools: DJC ML PS. Wrote the paper: LR JG PS ASP.</p>
        </fn>
        <fn id="fn1" fn-type="current-aff">
          <label>¤</label>
          <p>Current address: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States of America.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="collection">
        <month>3</month>
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>14</day>
        <month>3</month>
        <year>2013</year>
      </pub-date>
      <volume>9</volume>
      <issue>3</issue>
      <elocation-id>e1002959</elocation-id>
      <history>
        <date date-type="received">
          <day>23</day>
          <month>7</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>16</day>
          <month>1</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-year>2013</copyright-year>
        <license xlink:type="simple">
          <license-p>This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>The current paradigm for studying hepatitis C virus (HCV) dynamics in patients utilizes a standard viral dynamic model that keeps track of uninfected (target) cells, infected cells, and virus. The model does not account for the dynamics of intracellular viral replication, which is the major target of direct-acting antiviral agents (DAAs). Here we describe and study a recently developed multiscale age-structured model that explicitly considers the potential effects of DAAs on intracellular viral RNA production, degradation, and secretion as virus into the circulation. We show that when therapy significantly blocks both intracellular viral RNA production and virus secretion, the serum viral load decline has three phases, with slopes reflecting the rate of serum viral clearance, the rate of loss of intracellular viral RNA, and the rate of loss of intracellular replication templates and infected cells, respectively. We also derive analytical approximations of the multiscale model and use one of them to analyze data from patients treated for 14 days with the HCV protease inhibitor danoprevir. Analysis suggests that danoprevir significantly blocks intracellular viral production (with mean effectiveness 99.2%), enhances intracellular viral RNA degradation about 5-fold, and moderately inhibits viral secretion (with mean effectiveness 56%). The multiscale model can be used to study viral dynamics in patients treated with other DAAs and explore their mechanisms of action in treatment of hepatitis C.</p>
      </abstract>
      <abstract abstract-type="summary">
        <title>Author Summary</title>
        <p>Chronic infection with hepatitis C virus (HCV) remains an important health-care problem worldwide despite significant progress in the development of HCV therapy since the discovery of the virus in 1989. Current treatment options are focused on direct-acting antiviral agents (DAAs) that target specific steps of the HCV life cycle. Danoprevir, one of the DAAs that inhibit the HCV NS3-4A protease, has induced substantial viral load reductions in patients receiving therapy. We study the viral decline during therapy using a multiscale age-structured model that accounts for the dynamics of intracellular viral replication, and which includes the major steps in the HCV life cycle that are targeted by DAAs. We examine the biological parameters contributing to different phases of the viral decline after treatment initiation. We also explore the mechanisms of action of danoprevir and estimate its treatment effectiveness. The multiscale model provides a theoretical framework for studying virus dynamics in hepatitis C patients treated with other DAAs currently in clinical development, and may help one to optimally combine drugs with complementary modes of action to maximize the HCV cure rate.</p>
      </abstract>
      <funding-group>
        <funding-statement>Portions of this work were performed under the auspices of the U.S. Department of Energy under contract DE-AC52-06NA25396 and supported by NSF grants DMS-1122290 and PHY-1125915, NIH grants R56/R01-AI078881, P20-GM103452, AI028433, R34-HL109334 and OD011095, the University of Illinois Walter Payton Liver Center GUILD, and Roche, Inc. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
      </funding-group>
      <counts>
        <page-count count="12"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>Introduction</title>
      <p>Hepatitis C virus (HCV) infection is a major cause of chronic liver disease and a leading reason of liver transplant in the world. About 130–170 million people are chronically infected with HCV <xref ref-type="bibr" rid="pcbi.1002959-World1">[1]</xref>. Achieving a long-term sustained virologic response (SVR), defined as an undetectable HCV RNA level in serum 24 weeks after the end of treatment, is the most effective way to prevent disease progression <xref ref-type="bibr" rid="pcbi.1002959-Cardoso1">[2]</xref>. Until 2011, the standard of care for HCV infection has been the combination of weekly injection of pegylated-interferon and daily oral ribavirin (PEG-IFN/RBV). This treatment was limited by both tolerability and efficacy, with only about 50% of patients infected with HCV genotype 1, the most prevalent genotype in Western countries, achieving SVR <xref ref-type="bibr" rid="pcbi.1002959-Awad1">[3]</xref>.</p>
      <p>The approval in 2011 of two HCV protease inhibitors (PIs), telaprevir and boceprevir, to be used in combination with PEG-IFN/RBV, marked an undisputable milestone for HCV therapy, with the SVR rate in phase 3 clinical trials higher than 70% in HCV genotype 1 treatment-naive patients <xref ref-type="bibr" rid="pcbi.1002959-Poordad1">[4]</xref>–<xref ref-type="bibr" rid="pcbi.1002959-Bacon1">[8]</xref>. However, the enthusiasm for using these first generation PIs is tempered by their side effects and the emergence of resistance to treatment. A second generation of PIs, presenting better safety and resistance profiles, are now in various stages of clinical development, but their direct and indirect mechanisms of action and <italic>in vivo</italic> antiviral effectiveness remain unclear. Yet such information is critical for combining PIs with other direct-acting antiviral agents (DAAs) that have independent mechanisms of action to yield highly potent drug cocktails.</p>
      <p>Mathematical modeling of HCV kinetics has provided valuable insights into the modes of action of PEG-IFN/RBV <xref ref-type="bibr" rid="pcbi.1002959-Neumann1">[9]</xref>, <xref ref-type="bibr" rid="pcbi.1002959-Dixit1">[10]</xref> (also see review in <xref ref-type="bibr" rid="pcbi.1002959-Guedj1">[11]</xref>, <xref ref-type="bibr" rid="pcbi.1002959-Rong1">[12]</xref>). Nevertheless, models developed for PEG-IFN/RBV therapy may not be useful for understanding the determinants of viral decline during PI therapy since these models do not account for intracellular viral replication, which is the main target of DAAs. Recently, multiscale HCV models have been developed that combine both the intracellular and extracellular viral dynamics <xref ref-type="bibr" rid="pcbi.1002959-Guedj2">[13]</xref>, . One such model formulated as a system of ordinary differential equations (ODEs) was shown to be able to explain some patterns of viral kinetics observed during PI monotherapy, such as the rapid decline of drug sensitive virus and the rapid emergence of drug resistant virus <xref ref-type="bibr" rid="pcbi.1002959-Guedj2">[13]</xref>.</p>
      <p>In this paper, we use a multiscale model of HCV infection and treatment that includes the age structure of infected cells, as well as the dynamics of intracellular viral replication, in order to understand the effects of PI therapy. An approximation of this model was applied to understanding the kinetics of viral decline observed during the first two days following one dose of daclatasvir, a DAA that inhibits the HCV NS5A protein <xref ref-type="bibr" rid="pcbi.1002959-Guedj3">[14]</xref>. Here we formulate the model in detail, present its mathematical properties, and derive both short-term and long-term analytical approximations of the model under therapy. We then use the long-term approximation to fit viral kinetic data obtained from eight patients treated for two weeks with danoprevir, a potent second generation PI. We provide for the first time an estimate of the <italic>in vivo</italic> antiviral potency of danoprevir in blocking different stages of viral replication, e.g., reducing intracellular viral RNA production, enhancing its degradation, and inhibiting viral assembly or secretion.</p>
    </sec>
    <sec id="s2" sec-type="materials|methods">
      <title>Materials and Methods</title>
      <sec id="s2a">
        <title>Patient data</title>
        <p>The viral kinetic data we analyzed are from eight treatment naive patients who were infected with HCV genotype 1 and treated with danoprevir monotherapy (200 mg tablets three times a day) for 14 days <xref ref-type="bibr" rid="pcbi.1002959-Forestier1">[15]</xref>. Viral loads were measured post treatment initiation at hours 0 (baseline), 2, 4, 6, 8, 12, 16, 24 (day 1), 26, 28, 30, 48 (day 2), 52, 144 (day 6), 148, 192 (day 8), 196, 312 (day 13). The NS3 protease sequence was evaluated by population sequencing at days 0, 2, 6 and 13. Three patients 01-94AB, 03-94EZ, and 03-94SN were found to develop mutations conferring drug resistance, all of them at position R155K. The models we use to analyze the data assume that drug effectiveness is constant over the period of treatment. Hence these models are not suitable for analyzing patient data once drug resistance is apparent and we thus fit the data from these three patients until the time at which resistance was identified. As resistance data were missing at both days 2 and 6 in patients 01-94AB and 03-94SN, viral load data were fit until a rebound was observed at day 6 in 01-94AB and at day 2 in 03-94SN. One patient (04-94XD) had a viral load under the limit of quantification (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e001" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1002959-Forestier1">[15]</xref>) at day 14, and the data fit was done by setting this viral load to half of the limit of quantification. Data were fitted using both a standard biphasic model and a long-term approximation of the multiscale model developed in this study. Because drugs do not act instantaneously, we assumed the viral load began to decline a short time, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e002" xlink:type="simple"/></inline-formula>, after the onset of therapy.</p>
      </sec>
      <sec id="s2b">
        <title>The standard biphasic model</title>
        <p>The Neumann et al. model <xref ref-type="bibr" rid="pcbi.1002959-Neumann1">[9]</xref> has been extensively used to study HCV kinetics during treatment <xref ref-type="bibr" rid="pcbi.1002959-Neumann2">[16]</xref>–<xref ref-type="bibr" rid="pcbi.1002959-Adiwijaya1">[18]</xref> (see review in <xref ref-type="bibr" rid="pcbi.1002959-Guedj1">[11]</xref>, <xref ref-type="bibr" rid="pcbi.1002959-Rong1">[12]</xref>). In this model, target cells, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e003" xlink:type="simple"/></inline-formula>, are produced at a rate constant <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e004" xlink:type="simple"/></inline-formula>, die at per capita rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e005" xlink:type="simple"/></inline-formula>, and are infected by virus, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e006" xlink:type="simple"/></inline-formula>, at rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e007" xlink:type="simple"/></inline-formula>. Target cells are assumed to be equivalent and equally available to be infected. Infected cells are assumed to die at per capita rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e008" xlink:type="simple"/></inline-formula>. Virions are generated at rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e009" xlink:type="simple"/></inline-formula> per infected cell, and cleared at rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e010" xlink:type="simple"/></inline-formula> per virion. The model is formulated as the following set of ODEs:<disp-formula id="pcbi.1002959.e011"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1002959.e011" xlink:type="simple"/><label>(1)</label></disp-formula>Treatment is assumed to reduce the average viral production rate per infected cell from <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e012" xlink:type="simple"/></inline-formula> to <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e013" xlink:type="simple"/></inline-formula>, where <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e014" xlink:type="simple"/></inline-formula> is the <italic>in vivo</italic> antiviral effectiveness of therapy (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e015" xlink:type="simple"/></inline-formula>). If short-term data after treatment initiation are analyzed, it is often assumed that target cells remain at their pre-therapy level. As a consequence, the ODE system can be linearized and solved. Doing so, one finds<disp-formula id="pcbi.1002959.e016"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1002959.e016" xlink:type="simple"/><label>(2)</label></disp-formula>where <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e017" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e018" xlink:type="simple"/></inline-formula> is the baseline viral load before therapy, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e019" xlink:type="simple"/></inline-formula> is the pharmacological delay. This model predicts that viral load declines in a biphasic manner, where a short but rapid first phase is followed by a persistent but slower second phase. If <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e020" xlink:type="simple"/></inline-formula>, then <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e021" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e022" xlink:type="simple"/></inline-formula>. A limitation of this model is that it does not account for the specific stages of the HCV intracellular replication cycle that are targeted by different classes of DAAs and the possibly different effects they exert on the kinetics of viral decline.</p>
      </sec>
      <sec id="s2c">
        <title>A multiscale model</title>
        <p>We extend the biphasic model by including the dynamics of intracellular viral RNA (vRNA). Let <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e023" xlink:type="simple"/></inline-formula> be the quantity of intracellular genomic (i.e. positive-strand) vRNA present in an infected cell. The dynamics of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e024" xlink:type="simple"/></inline-formula> depend on the tradeoff between vRNA production and loss due to degradation and assembly/secretion as virions and can be described by the following equation<disp-formula id="pcbi.1002959.e025"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1002959.e025" xlink:type="simple"/><label>(3)</label></disp-formula>where <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e026" xlink:type="simple"/></inline-formula> is the age of infection, i.e., the time that has elapsed since an HCV virion has entered the cell. The parameters <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e027" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e028" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e029" xlink:type="simple"/></inline-formula> are the age-dependent rates of vRNA production, degradation and assembly/secretion, respectively. For simplicity we do not distinguish between vRNA being packaged into a virion and the virion being secreted. Once vRNA is packaged it is no longer available for replication or degradation, and we assume the packaged virion is secreted. A more complex model would distinguish these processes but at the expense of additional parameters. We assume that a cell is infected by a single virion and hence there is only one vRNA in an infected cell at age 0, i.e., <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e030" xlink:type="simple"/></inline-formula>. A model similar to <xref ref-type="disp-formula" rid="pcbi.1002959.e025">Eq. (3)</xref> but with constant parameters has been successfully used to fit intracellular vRNA levels in an in vitro replicon system <xref ref-type="bibr" rid="pcbi.1002959-Dahari1">[19]</xref>, giving us confidence that a simple model can capture many of the major events in vRNA replication. More complex models exist (e.g., Dahari et al. <xref ref-type="bibr" rid="pcbi.1002959-Dahari2">[20]</xref> in which the model has 9 equations and 18 parameters) but because they involve many parameters whose values are not known as well as many other intracellular molecules they are not well suited for our purpose here of understanding the major effects of PI therapy.</p>
        <p>Combining the equations governing the vRNA kinetics and the cell infection dynamics given by <xref ref-type="disp-formula" rid="pcbi.1002959.e011">Eq. (1)</xref>, an age-structured multiscale model of HCV kinetics results that can be described by the following partial differential equations (PDE):<disp-formula id="pcbi.1002959.e031"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1002959.e031" xlink:type="simple"/><label>(4)</label></disp-formula>The initial distributions of infected cells and intracellular vRNAs are assumed to be <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e032" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e033" xlink:type="simple"/></inline-formula>, respectively. If <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e034" xlink:type="simple"/></inline-formula> is chosen to be the time of initial infection, then <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e035" xlink:type="simple"/></inline-formula>. The <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e036" xlink:type="simple"/></inline-formula> equation would become an ODE (<xref ref-type="disp-formula" rid="pcbi.1002959.e025">Eq. 3</xref>) if <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e037" xlink:type="simple"/></inline-formula> were the steady state distribution since no further time evolution would occur.</p>
        <p>Unlike the standard biphasic model, three different antiviral effects of therapy with DAAs can be distinguished in the multiscale model, namely blocking vRNA production (i.e., reducing <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e038" xlink:type="simple"/></inline-formula> by a factor <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e039" xlink:type="simple"/></inline-formula>), reducing assembly/secretion of virus (i.e., reducing <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e040" xlink:type="simple"/></inline-formula> by a factor <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e041" xlink:type="simple"/></inline-formula>), and enhancing the rate of vRNA degradation (i.e., increasing <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e042" xlink:type="simple"/></inline-formula> by a factor <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e043" xlink:type="simple"/></inline-formula>), where <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e044" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e045" xlink:type="simple"/></inline-formula> are the effectivenesses of therapy in affecting different processes in the viral life cycle. The full model combining both intra and extracellular viral kinetics under therapy is<disp-formula id="pcbi.1002959.e046"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1002959.e046" xlink:type="simple"/><label>(5)</label></disp-formula>where <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e047" xlink:type="simple"/></inline-formula> is the time at which treatment is initiated, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e048" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e049" xlink:type="simple"/></inline-formula> are the steady state distribution of infected cells and intracellular vRNAs, respectively, before therapy, which will be calculated in <xref ref-type="sec" rid="s3">Results</xref>. An additional potential antiviral effect of the therapy on intracellular replication templates will be incorporated into the model later (see the subsection of Long-term Approximation).</p>
      </sec>
    </sec>
    <sec id="s3">
      <title>Results</title>
      <sec id="s3a">
        <title>Analysis of viral decline data using the standard biphasic model</title>
        <p>We first fit the patient data using the standard biphasic model (<xref ref-type="disp-formula" rid="pcbi.1002959.e016">Eq. 2</xref>). There are 5 parameters in the prediction of viral decline, including the baseline viral load <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e050" xlink:type="simple"/></inline-formula> and the pharmacological delay <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e051" xlink:type="simple"/></inline-formula>. Because of the lack of frequent sampling in the first several hours after treatment initiation, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e052" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e053" xlink:type="simple"/></inline-formula> could not be estimated precisely. Thus, we fixed <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e054" xlink:type="simple"/></inline-formula> to the last observed viral load before continuous viral reduction was observed, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e055" xlink:type="simple"/></inline-formula> was defined as the mean between the time when <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e056" xlink:type="simple"/></inline-formula> was measured and the time of the next observed data point. For instance, with the sampling of this study, if the last viral load measurement before the viral decline was at 2 hours, and the next viral load was taken at 4 hours, then <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e057" xlink:type="simple"/></inline-formula> hours. An alternative would be to fix <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e058" xlink:type="simple"/></inline-formula> to the time for danoprevir to reach its maximum serum concentration, but as liver concentrations differ we prefer the method given above. The other 3 parameters, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e059" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e060" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e061" xlink:type="simple"/></inline-formula> were estimated by non-linear least squares regression using the Levenberg-Marquardt algorithm <xref ref-type="bibr" rid="pcbi.1002959-Marquardt1">[21]</xref>.</p>
        <p>The biphasic model provides good fits to patient data. The best fits are shown in <xref ref-type="fig" rid="pcbi-1002959-g001">Figure 1</xref> (red dashed line). Estimates of parameter values on the basis of the best fits are given in <xref ref-type="table" rid="pcbi-1002959-t001">Table 1</xref>. The biphasic model predicts that danoprevir blocks viral production with mean effectiveness <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e062" xlink:type="simple"/></inline-formula>. For this model, the slopes of the first-phase and second-phase viral decline reflect the viral clearance rate, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e063" xlink:type="simple"/></inline-formula>, and the death rate of infected cells, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e064" xlink:type="simple"/></inline-formula>, respectively. The average estimates of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e065" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e066" xlink:type="simple"/></inline-formula> are <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e067" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e068" xlink:type="simple"/></inline-formula>, respectively (<xref ref-type="table" rid="pcbi-1002959-t001">Table 1</xref>). These values are substantially greater than what was typically found during IFN-based therapy <xref ref-type="bibr" rid="pcbi.1002959-Neumann1">[9]</xref>, where <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e069" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e070" xlink:type="simple"/></inline-formula> are in the order of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e071" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e072" xlink:type="simple"/></inline-formula>, respectively. Interestingly, in another study <xref ref-type="bibr" rid="pcbi.1002959-Guedj3">[14]</xref> in which the biphasic model was used to analyze HCV viral decline in patients receiving the HCV NS5A inhibitor daclatasvir, the average estimates of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e073" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e074" xlink:type="simple"/></inline-formula> were <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e075" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e076" xlink:type="simple"/></inline-formula>, respectively, which are also significantly higher than estimates during IFN-based therapy. It is unlikely that the administration of DAAs such as danoprevir or daclatasvir will enhance the clearance rate of virus, although they could lead to higher estimates of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e077" xlink:type="simple"/></inline-formula> by causing the loss of intracellular viral RNA <xref ref-type="bibr" rid="pcbi.1002959-Guedj2">[13]</xref> and ultimately the “cure” of infected cells as has been seen in vitro <xref ref-type="bibr" rid="pcbi.1002959-Lin1">[22]</xref>, <xref ref-type="bibr" rid="pcbi.1002959-Blight1">[23]</xref>. To model this effect, as well as to explain the higher value of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e078" xlink:type="simple"/></inline-formula> seen with DAAs, we introduce a multiscale model (<xref ref-type="disp-formula" rid="pcbi.1002959.e046">Eq. 5</xref>) that accounts for the different stages of intracellular viral replication that are specifically targeted by DAAs.</p>
        <fig id="pcbi-1002959-g001" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pcbi.1002959.g001</object-id>
          <label>Figure 1</label>
          <caption>
            <title>Comparison of viral load data with model predictions for each patient.</title>
            <p>The prediction from the standard biphasic model is shown by the red dashed line and the prediction from the long-term approximation of the full multiscale model is shown by the black solid line. In most cases the two predicted viral load decay curves overlap and cannot be distinguished. The parameter values used to generate the theoretical curves are the best fit values given in <xref ref-type="table" rid="pcbi-1002959-t001">Table 1</xref> and <xref ref-type="table" rid="pcbi-1002959-t002">2</xref>, respectively. Viral rebounds occur due to drug resistance and the decay data (circles) was only fit until resistance was detected or rebound was observed. The limit of viral load detection is indicated by the black dashed line.</p>
          </caption>
          <graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002959.g001" position="float" xlink:type="simple"/>
        </fig>
        <table-wrap id="pcbi-1002959-t001" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pcbi.1002959.t001</object-id>
          <label>Table 1</label>
          <caption>
            <title>Parameter values with standard errors in parenthesis estimated by fitting the standard biphasic model to viral load data.</title>
          </caption>
          <alternatives>
            <graphic id="pcbi-1002959-t001-1" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002959.t001" xlink:type="simple"/>
            <table>
              <colgroup span="1">
                <col align="left" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Patient</td>
                  <td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e079" xlink:type="simple"/></inline-formula> (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e080" xlink:type="simple"/></inline-formula>)</td>
                  <td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e081" xlink:type="simple"/></inline-formula> (days)</td>
                  <td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e082" xlink:type="simple"/></inline-formula> (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e083" xlink:type="simple"/></inline-formula>)</td>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e084" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e085" xlink:type="simple"/></inline-formula> (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e086" xlink:type="simple"/></inline-formula>)</td>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td align="left" rowspan="1" colspan="1">01-94AB</td>
                  <td align="left" rowspan="1" colspan="1">6.24</td>
                  <td align="left" rowspan="1" colspan="1">0.12</td>
                  <td align="left" rowspan="1" colspan="1">11.50 (0.80)</td>
                  <td align="left" rowspan="1" colspan="1">0.999 (0.000066)</td>
                  <td align="left" rowspan="1" colspan="1">0.42 (0.060)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">01-94GK</td>
                  <td align="left" rowspan="1" colspan="1">7.24</td>
                  <td align="left" rowspan="1" colspan="1">0.12</td>
                  <td align="left" rowspan="1" colspan="1">7.38 (0.33)</td>
                  <td align="left" rowspan="1" colspan="1">0.9995 (0.000071)</td>
                  <td align="left" rowspan="1" colspan="1">0.15 (0.019)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">03-94EA</td>
                  <td align="left" rowspan="1" colspan="1">5.79</td>
                  <td align="left" rowspan="1" colspan="1">0.04</td>
                  <td align="left" rowspan="1" colspan="1">10.50 (0.72)</td>
                  <td align="left" rowspan="1" colspan="1">0.998 (0.00022)</td>
                  <td align="left" rowspan="1" colspan="1">0.17 (0.037)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">03-94EZ</td>
                  <td align="left" rowspan="1" colspan="1">6.56</td>
                  <td align="left" rowspan="1" colspan="1">0.12</td>
                  <td align="left" rowspan="1" colspan="1">11.35 (0.76)</td>
                  <td align="left" rowspan="1" colspan="1">0.998 (0.00060)</td>
                  <td align="left" rowspan="1" colspan="1">0.65 (0.35)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">03-94HD</td>
                  <td align="left" rowspan="1" colspan="1">6.72</td>
                  <td align="left" rowspan="1" colspan="1">0.04</td>
                  <td align="left" rowspan="1" colspan="1">12.44 (1.07)</td>
                  <td align="left" rowspan="1" colspan="1">0.998 (0.00036)</td>
                  <td align="left" rowspan="1" colspan="1">0.29 (0.038)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">03-94KG</td>
                  <td align="left" rowspan="1" colspan="1">6.98</td>
                  <td align="left" rowspan="1" colspan="1">0.04</td>
                  <td align="left" rowspan="1" colspan="1">9.40 (1.16)</td>
                  <td align="left" rowspan="1" colspan="1">0.98 (0.0034)</td>
                  <td align="left" rowspan="1" colspan="1">0.35 (0.035)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">03-94SN</td>
                  <td align="left" rowspan="1" colspan="1">5.74</td>
                  <td align="left" rowspan="1" colspan="1">0.04</td>
                  <td align="left" rowspan="1" colspan="1">10.03 (0.61)</td>
                  <td align="left" rowspan="1" colspan="1">0.997 (0.00090)</td>
                  <td align="left" rowspan="1" colspan="1">1.0 (0.32)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">04-94XD</td>
                  <td align="left" rowspan="1" colspan="1">6.63</td>
                  <td align="left" rowspan="1" colspan="1">0.12</td>
                  <td align="left" rowspan="1" colspan="1">10.26 (0.69)</td>
                  <td align="left" rowspan="1" colspan="1">0.9995 (0.00063)</td>
                  <td align="left" rowspan="1" colspan="1">0.33 (0.040)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>Mean</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e087" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e088" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e089" xlink:type="simple"/>
                    </inline-formula>
                    <xref ref-type="table-fn" rid="nt101">1</xref>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e090" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e091" xlink:type="simple"/>
                    </inline-formula>
                    <xref ref-type="table-fn" rid="nt102">2</xref>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>SD</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e092" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e093" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e094" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e095" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e096" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                </tr>
              </tbody>
            </table>
          </alternatives>
          <table-wrap-foot>
            <fn id="nt101">
              <label>1</label>
              <p>Corresponding to a half-life <italic>t</italic><sub>1/2</sub> = 0.067 days.</p>
            </fn>
            <fn id="nt102">
              <label>2</label>
              <p>Corresponding to a half-life <italic>t</italic><sub>1/2</sub> = 1.65 days.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="s3b">
        <title>Analysis of the multiscale model</title>
        <p>We analyze the multiscale model and derive analytical approximations that will be used to fit patient data. We begin with the infected steady state of the pre-therapy model (4). For the pre-therapy model, we note that <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e097" xlink:type="simple"/></inline-formula> can be any time and does not have to be the time of initial infection. For example, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e098" xlink:type="simple"/></inline-formula> could be the time one starts observing an infected patient. If the patient has not been infected for too long then the steady state has not been reached. A full analysis is needed to determine if the solution of the system will converge to the steady state.</p>
        <p>Let<disp-formula id="pcbi.1002959.e099"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1002959.e099" xlink:type="simple"/><label>(6)</label></disp-formula>Then <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e100" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e101" xlink:type="simple"/></inline-formula> can be interpreted as the probability of an infected cell and an intracellular vRNA surviving to age <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e102" xlink:type="simple"/></inline-formula>, respectively. At steady state, the density of infected cells that have an age <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e103" xlink:type="simple"/></inline-formula> is<disp-formula id="pcbi.1002959.e104"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1002959.e104" xlink:type="simple"/><label>(7)</label></disp-formula>where <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e105" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e106" xlink:type="simple"/></inline-formula> are the steady-state viral load and target cells, respectively. The steady-state level of vRNA within an infected cell of age <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e107" xlink:type="simple"/></inline-formula> is<disp-formula id="pcbi.1002959.e108"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1002959.e108" xlink:type="simple"/><label>(8)</label></disp-formula>When <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e109" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e110" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e111" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e112" xlink:type="simple"/></inline-formula> are all constants, we have <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e113" xlink:type="simple"/></inline-formula>, and<disp-formula id="pcbi.1002959.e114"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1002959.e114" xlink:type="simple"/><label>(9)</label></disp-formula>Plugging <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e115" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e116" xlink:type="simple"/></inline-formula> into the <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e117" xlink:type="simple"/></inline-formula> equation in (4), we have<disp-formula id="pcbi.1002959.e118"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1002959.e118" xlink:type="simple"/><label>(10)</label></disp-formula>Let<disp-formula id="pcbi.1002959.e119"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1002959.e119" xlink:type="simple"/><label>(11)</label></disp-formula>Thus, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e120" xlink:type="simple"/></inline-formula> gives the total number of virions produced by one infected cell over its lifespan. This number is usually called the viral burst size <xref ref-type="bibr" rid="pcbi.1002959-Nelson1">[24]</xref>, <xref ref-type="bibr" rid="pcbi.1002959-Rong2">[25]</xref>. Solving <xref ref-type="disp-formula" rid="pcbi.1002959.e119">Eq. (11)</xref>, we obtain <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e121" xlink:type="simple"/></inline-formula>. From the first equation of (4), we obtain the steady-state viral load, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e122" xlink:type="simple"/></inline-formula>. Substituting <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e123" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e124" xlink:type="simple"/></inline-formula> into <xref ref-type="disp-formula" rid="pcbi.1002959.e118">Eq. (10)</xref>, we obtain <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e125" xlink:type="simple"/></inline-formula>. Let <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e126" xlink:type="simple"/></inline-formula>. <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e127" xlink:type="simple"/></inline-formula> is the basic reproductive ratio of model (4). The infected steady state (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e128" xlink:type="simple"/></inline-formula>) of model (4) is feasible, i.e. has all variables positive, if and only if <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e129" xlink:type="simple"/></inline-formula>. In <xref ref-type="supplementary-material" rid="pcbi.1002959.s001">Text S1</xref>, we further show that the infection-free steady state is locally asymptotically stable when <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e130" xlink:type="simple"/></inline-formula> and unstable when <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e131" xlink:type="simple"/></inline-formula>, and that the infected steady state is locally asymptotically stable whenever it exists, i.e., when <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e132" xlink:type="simple"/></inline-formula>.</p>
      </sec>
      <sec id="s3c">
        <title>Approximation solutions of the multiscale model under therapy</title>
        <p>We assume that <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e133" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e134" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e135" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e136" xlink:type="simple"/></inline-formula> are all constants. Using the method of characteristics one can then show that (see <xref ref-type="supplementary-material" rid="pcbi.1002959.s001">Text S1</xref>) after initiation of therapy at time <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e137" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e138" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e139" xlink:type="simple"/></inline-formula> are<disp-formula id="pcbi.1002959.e140"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1002959.e140" xlink:type="simple"/><label>(12)</label></disp-formula><disp-formula id="pcbi.1002959.e141"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1002959.e141" xlink:type="simple"/><label>(13)</label></disp-formula>where<disp-formula id="pcbi.1002959.e142"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1002959.e142" xlink:type="simple"/><label>(14)</label></disp-formula>and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e143" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e144" xlink:type="simple"/></inline-formula> are the steady-state distributions, given in <xref ref-type="disp-formula" rid="pcbi.1002959.e114">Eq. (9)</xref>. Even though the distributions of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e145" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e146" xlink:type="simple"/></inline-formula> have an analytical form, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e147" xlink:type="simple"/></inline-formula> does not. Consequently, the implementation of the full multiscale PDE model and its use for fitting viral load data involve cumbersome calculations. Therefore, it is important to study whether reasonable assumptions can be made to derive relevant analytical approximations of this model in the context of DAA-based therapy.</p>
        <sec id="s3c1">
          <title>Short-term approximation</title>
          <p>We first approximate the viral load decline by assuming that after therapy is initiated infected cells remain at their steady-state distribution, i.e., <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e148" xlink:type="simple"/></inline-formula>. This is equivalent to assuming that new infections (corresponding to the case of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e149" xlink:type="simple"/></inline-formula>) after treatment initiation still occur at the same rate as before treatment. This assumption is reasonable only for a short time after therapy initiation because the rate of new infections will decline in the presence of effective treatment. With this assumption, the total number of infected cells is <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e150" xlink:type="simple"/></inline-formula>, which is exactly the number of infected cells before therapy in the standard biphasic model (2). Assuming that infected cells remain at their pre-therapy level was also used in <xref ref-type="bibr" rid="pcbi.1002959-Neumann1">[9]</xref> to study the short-term viral decline under IFN therapy.</p>
          <p>Using <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e151" xlink:type="simple"/></inline-formula> in <xref ref-type="disp-formula" rid="pcbi.1002959.e140">Eq. (12)</xref>, we solve the <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e152" xlink:type="simple"/></inline-formula> equation in model (5) and obtain (see <xref ref-type="supplementary-material" rid="pcbi.1002959.s001">Text S1</xref>)<disp-formula id="pcbi.1002959.e153"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1002959.e153" xlink:type="simple"/><label>(15)</label></disp-formula>where<disp-formula id="pcbi.1002959.e154"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1002959.e154" xlink:type="simple"/></disp-formula><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e155" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e156" xlink:type="simple"/></inline-formula> are given in (14), and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e157" xlink:type="simple"/></inline-formula> is the baseline viral load before the onset of therapy. Because the assumption of a constant rate of new infection is reasonable only for a short period after therapy initiation, we call <xref ref-type="disp-formula" rid="pcbi.1002959.e153">Eq. (15)</xref> a short-term approximation of the viral decline after therapy.</p>
        </sec>
        <sec id="s3c2">
          <title>Long-term approximation</title>
          <p>Alternatively, we can approximate the viral load decline by neglecting all new infections after the onset of therapy, i.e. assuming <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e158" xlink:type="simple"/></inline-formula> for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e159" xlink:type="simple"/></inline-formula>. This is reasonable if therapy is potent enough so that viral levels decline profoundly and continuously after therapy is initiated. From <xref ref-type="disp-formula" rid="pcbi.1002959.e140">Eq. (12)</xref>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e160" xlink:type="simple"/></inline-formula> converges to a non-zero steady state solution <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e161" xlink:type="simple"/></inline-formula>. However, this may not be realistic as <italic>in vitro</italic> cell culture systems have shown that under potent therapy vRNA declines continuously and that a complete eradication of vRNA can be obtained after weeks of treatment <xref ref-type="bibr" rid="pcbi.1002959-Lin1">[22]</xref>, <xref ref-type="bibr" rid="pcbi.1002959-Blight1">[23]</xref>. Consequently, to study long-term therapy we modify the equation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e162" xlink:type="simple"/></inline-formula> by introducing a new term, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e163" xlink:type="simple"/></inline-formula>, which represents the decay of replication templates (e.g. replication complexes or negative strand HCV RNA) under therapy. Such an exponential term was also used in a model in <xref ref-type="bibr" rid="pcbi.1002959-Dahari1">[19]</xref> to fit intracellular vRNA levels in an in vitro replicon system. A more complete model would include another intracellular equation for replication complexes (such as the equation in <xref ref-type="bibr" rid="pcbi.1002959-Guedj2">[13]</xref>) but would involve more unknown parameters (see <xref ref-type="sec" rid="s4">Discussion</xref>). In fact, we show in <xref ref-type="supplementary-material" rid="pcbi.1002959.s001">Text S1</xref> that the inclusion of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e164" xlink:type="simple"/></inline-formula> in the <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e165" xlink:type="simple"/></inline-formula> equation is consistent with the formulation of the intracellular model in <xref ref-type="bibr" rid="pcbi.1002959-Guedj2">[13]</xref> that explicitly includes the dynamics of replication templates.</p>
          <p>With an exponential decay in vRNA production during treatment, the <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e166" xlink:type="simple"/></inline-formula> equation becomes<disp-formula id="pcbi.1002959.e167"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1002959.e167" xlink:type="simple"/><label>(16)</label></disp-formula>with the initial condition <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e168" xlink:type="simple"/></inline-formula> given in (9).</p>
          <p>Using this new equation for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e169" xlink:type="simple"/></inline-formula> and neglecting all new infections after the onset of therapy, we obtain (see <xref ref-type="supplementary-material" rid="pcbi.1002959.s001">Text S1</xref>)<disp-formula id="pcbi.1002959.e170"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1002959.e170" xlink:type="simple"/><label>(17)</label></disp-formula>In this approximation, we neglect all new infections during therapy. This is reasonable after therapy has substantially reduced the viral load. Thus, we call Eq. (17) a long-term approximation of the viral decline after therapy.</p>
        </sec>
        <sec id="s3c3">
          <title>Numerical comparisons</title>
          <p>Under effective drug therapy, the viral load decreases and the rate of new infections, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e171" xlink:type="simple"/></inline-formula>, also decreases. Thus, we have <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e172" xlink:type="simple"/></inline-formula>. From the assumptions used to derive approximations, we expect that <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e173" xlink:type="simple"/></inline-formula> given by the short-term approximation is greater than the prediction of the PDE model, which in turn is greater than the long-term approximation. Numerical results confirm these predictions. In <xref ref-type="fig" rid="pcbi-1002959-g002">Figure 2A</xref>, we show that the short-term approximation agrees well with the solution of the PDE model during the early stage of therapy. However, the short-term approximation approaches a steady state quickly, which is greater than the solution of the multiscale PDE model. In <xref ref-type="fig" rid="pcbi-1002959-g002">Figure 2B</xref>, we compare the long-term approximation with the numerical solution of the PDE model. The long-term approximation is an underestimate of the PDE solution. However, in the parameter range of interest the difference between them is extremely small and the long-term approximation converges to the PDE solution quickly (<xref ref-type="fig" rid="pcbi-1002959-g002">Figure 2B</xref>).</p>
          <fig id="pcbi-1002959-g002" position="float">
            <object-id pub-id-type="doi">10.1371/journal.pcbi.1002959.g002</object-id>
            <label>Figure 2</label>
            <caption>
              <title>The approximate and the numerical solutions of the multiscale model.</title>
              <p><bold>A.</bold> The short-term approximation (blue solid) is compared with the solution of the multiscale PDE model (black dashed). <bold>B.</bold> Difference between the long-term approximation and the solution of the multiscale PDE model. Parameter values, chosen from <xref ref-type="table" rid="pcbi-1002959-t002">Table 2</xref> and <xref ref-type="bibr" rid="pcbi.1002959-Rong3">[30]</xref>, are <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e174" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e175" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e176" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e177" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e178" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e179" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e180" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e181" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e182" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e183" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e184" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e185" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e186" xlink:type="simple"/></inline-formula>.</p>
            </caption>
            <graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002959.g002" position="float" xlink:type="simple"/>
          </fig>
        </sec>
        <sec id="s3c4">
          <title>Duration of the phases of viral decline</title>
          <p>The presence of three exponential terms in the long-term approximation <xref ref-type="disp-formula" rid="pcbi.1002959.e170">Eq. (17)</xref> implies that the multiscale model, unlike the standard biphasic model, may have as many as three phases of viral load decline during therapy. The first exponential term represents the clearance of virus from the circulation (with rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e187" xlink:type="simple"/></inline-formula>). The other two terms represent loss of the material needed to make new virus through a combination of processes. The second exponential term represents the loss of intracellular vRNA by export and degradation as well as the elimination of infected cells (with rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e188" xlink:type="simple"/></inline-formula>), while the third term represents the reduction in vRNA due to loss of replication templates in infected cells as well as the elimination of infected cells (with combined rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e189" xlink:type="simple"/></inline-formula>).</p>
          <p>Three exponential terms do not mean that a triphasic viral decline will always be observed during therapy. In fact, we show in <xref ref-type="supplementary-material" rid="pcbi.1002959.s001">Text S1</xref> that the rapid first phase of viral decline with rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e190" xlink:type="simple"/></inline-formula> will be observed only if therapy efficiently blocks viral assembly or secretion, i.e. if <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e191" xlink:type="simple"/></inline-formula> is close to 1. Moreover, in this case we calculated that the first-phase viral decline may not last more than 8 hours based on parameter values estimated from data fitting. Therefore, the rapid first-phase viral decline may not be identified from clinical data if viral load measurements are not taken very frequently after the initiation of treatment. We show in <xref ref-type="supplementary-material" rid="pcbi.1002959.s001">Text S1</xref> that there will not be a visible second-phase viral decline (with the slope <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e192" xlink:type="simple"/></inline-formula>) unless <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e193" xlink:type="simple"/></inline-formula>, the effectiveness of therapy in blocking intracellular viral production, is close to 1. Numerical simulations with different combinations of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e194" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e195" xlink:type="simple"/></inline-formula> confirm these predictions (<xref ref-type="fig" rid="pcbi-1002959-g003">Figure 3</xref>). In <xref ref-type="supplementary-material" rid="pcbi.1002959.s001">Text S1</xref>, we also show the effect of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e196" xlink:type="simple"/></inline-formula> on the viral load decline. Changing <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e197" xlink:type="simple"/></inline-formula> only affects the phase of viral decline with slope <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e198" xlink:type="simple"/></inline-formula>.</p>
          <fig id="pcbi-1002959-g003" position="float">
            <object-id pub-id-type="doi">10.1371/journal.pcbi.1002959.g003</object-id>
            <label>Figure 3</label>
            <caption>
              <title>Phases of viral decline affected by the effectiveness of therapy in blocking intracellular viral production and assembly/secretion.</title>
              <p>When therapy significantly blocks both intracellular viral production (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e199" xlink:type="simple"/></inline-formula>) and assembly/secretion (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e200" xlink:type="simple"/></inline-formula>), the viral load decline has three phases (blue solid), with slopes <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e201" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e202" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e203" xlink:type="simple"/></inline-formula>, respectively. The duration of the first phase (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e204" xlink:type="simple"/></inline-formula>) is about 0.25 days and the duration of the second phase (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e205" xlink:type="simple"/></inline-formula>) is about 0.88 days using the parameter values below. When <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e206" xlink:type="simple"/></inline-formula>, the first-phase viral decline with the slope <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e207" xlink:type="simple"/></inline-formula> is not visible (red dashed). When <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e208" xlink:type="simple"/></inline-formula>, the second-phase viral decline is not visible (black dash-dotted). Parameter values <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e209" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e210" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e211" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e212" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e213" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e214" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e215" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e216" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e217" xlink:type="simple"/></inline-formula> are from <xref ref-type="table" rid="pcbi-1002959-t002">Table 2</xref>. Because <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e218" xlink:type="simple"/></inline-formula> was chosen to be 0, when comparing the predicted duration of the first phase in this figure with clinical data one may want to add the length of the pharmacological delay to <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e219" xlink:type="simple"/></inline-formula>.</p>
            </caption>
            <graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002959.g003" position="float" xlink:type="simple"/>
          </fig>
        </sec>
      </sec>
      <sec id="s3d">
        <title>Analysis of viral decline data using the multiscale model</title>
        <p>We analyzed patient data using the long-term approximation of the multiscale model under therapy. The long-term approximation (<xref ref-type="disp-formula" rid="pcbi.1002959.e170">Eq. 17</xref>) has 11 parameters, including the baseline viral load <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e220" xlink:type="simple"/></inline-formula> and the pharmacological delay <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e221" xlink:type="simple"/></inline-formula>. We chose <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e222" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e223" xlink:type="simple"/></inline-formula> to have the same values as determined for the biphasic model (<xref ref-type="table" rid="pcbi-1002959-t001">Table 1</xref>). Because parameters that are not related to treatment should not depend upon the DAA being used, we chose <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e224" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e225" xlink:type="simple"/></inline-formula> (corresponding to a half-life <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e226" xlink:type="simple"/></inline-formula> minutes), <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e227" xlink:type="simple"/></inline-formula> (corresponding to <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e228" xlink:type="simple"/></inline-formula> days), <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e229" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e230" xlink:type="simple"/></inline-formula> (<xref ref-type="table" rid="pcbi-1002959-t002">Table 2</xref>), which are consistent with what was estimated <italic>in vitro</italic> <xref ref-type="bibr" rid="pcbi.1002959-Dahari3">[26]</xref> and also in patients treated with daclatasvir <xref ref-type="bibr" rid="pcbi.1002959-Guedj3">[14]</xref> and IFN <xref ref-type="bibr" rid="pcbi.1002959-Neumann1">[9]</xref>. The remaining parameters were the four treatment effectiveness parameters <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e231" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e232" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e233" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e234" xlink:type="simple"/></inline-formula> and these were estimated using the same method as used for the biphasic model. Note that changing <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e235" xlink:type="simple"/></inline-formula> will affect <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e236" xlink:type="simple"/></inline-formula> since only <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e237" xlink:type="simple"/></inline-formula> can be estimated. Similarly, changing <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e238" xlink:type="simple"/></inline-formula> will mainly affect <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e239" xlink:type="simple"/></inline-formula> because <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e240" xlink:type="simple"/></inline-formula> is estimated from the slope of the last phase of viral decline (<xref ref-type="fig" rid="pcbi-1002959-g003">Figure 3</xref>).</p>
        <table-wrap id="pcbi-1002959-t002" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pcbi.1002959.t002</object-id>
          <label>Table 2</label>
          <caption>
            <title>Parameter values with standard errors in parenthesis estimated by fitting the long-term approximation to viral load data and assuming <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e241" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e242" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e243" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e244" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e245" xlink:type="simple"/></inline-formula>.</title>
          </caption>
          <alternatives>
            <graphic id="pcbi-1002959-t002-2" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002959.t002" xlink:type="simple"/>
            <table>
              <colgroup span="1">
                <col align="left" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Patient</td>
                  <td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e246" xlink:type="simple"/></inline-formula> (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e247" xlink:type="simple"/></inline-formula>)</td>
                  <td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e248" xlink:type="simple"/></inline-formula> (days)</td>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e249" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e250" xlink:type="simple"/></inline-formula> (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e251" xlink:type="simple"/></inline-formula>)</td>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e252" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e253" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td align="left" rowspan="1" colspan="1">01-94AB</td>
                  <td align="left" rowspan="1" colspan="1">6.24</td>
                  <td align="left" rowspan="1" colspan="1">0.12</td>
                  <td align="left" rowspan="1" colspan="1">6.64 (0.50)</td>
                  <td align="left" rowspan="1" colspan="1">0.23 (0.056)</td>
                  <td align="left" rowspan="1" colspan="1">0.997 (0.00066)</td>
                  <td align="left" rowspan="1" colspan="1">0.78 (0.060)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">01-94GK</td>
                  <td align="left" rowspan="1" colspan="1">7.24</td>
                  <td align="left" rowspan="1" colspan="1">0.12</td>
                  <td align="left" rowspan="1" colspan="1">3.52 (0.22)</td>
                  <td align="left" rowspan="1" colspan="1">−0.014<xref ref-type="table-fn" rid="nt103">1</xref> (0.022)</td>
                  <td align="left" rowspan="1" colspan="1">0.999 (0.00015)</td>
                  <td align="left" rowspan="1" colspan="1">0.69 (0.051)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">03-94EA</td>
                  <td align="left" rowspan="1" colspan="1">5.79</td>
                  <td align="left" rowspan="1" colspan="1">0.04</td>
                  <td align="left" rowspan="1" colspan="1">5.97 (1.18)</td>
                  <td align="left" rowspan="1" colspan="1">0.0003 (0.047)</td>
                  <td align="left" rowspan="1" colspan="1">0.994 (0.0025)</td>
                  <td align="left" rowspan="1" colspan="1">0.71 (0.18)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">03-94EZ</td>
                  <td align="left" rowspan="1" colspan="1">6.56</td>
                  <td align="left" rowspan="1" colspan="1">0.12</td>
                  <td align="left" rowspan="1" colspan="1">6.24 (1.64)</td>
                  <td align="left" rowspan="1" colspan="1">0.55 (0.32)</td>
                  <td align="left" rowspan="1" colspan="1">0.996 (0.0020)</td>
                  <td align="left" rowspan="1" colspan="1">0.13 (0.34)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">03-94HD</td>
                  <td align="left" rowspan="1" colspan="1">6.72</td>
                  <td align="left" rowspan="1" colspan="1">0.04</td>
                  <td align="left" rowspan="1" colspan="1">4.07 (0.93)</td>
                  <td align="left" rowspan="1" colspan="1">0.095 (0.048)</td>
                  <td align="left" rowspan="1" colspan="1">0.99 (0.0040)</td>
                  <td align="left" rowspan="1" colspan="1">0.92 (0.036)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">03-94KG</td>
                  <td align="left" rowspan="1" colspan="1">6.98</td>
                  <td align="left" rowspan="1" colspan="1">0.04</td>
                  <td align="left" rowspan="1" colspan="1">4.19 (1.46)</td>
                  <td align="left" rowspan="1" colspan="1">0.20 (0.036)</td>
                  <td align="left" rowspan="1" colspan="1">0.97 (0.012)</td>
                  <td align="left" rowspan="1" colspan="1">0.55 (0.25)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">03-94SN</td>
                  <td align="left" rowspan="1" colspan="1">5.74</td>
                  <td align="left" rowspan="1" colspan="1">0.04</td>
                  <td align="left" rowspan="1" colspan="1">4.10 (0.72)</td>
                  <td align="left" rowspan="1" colspan="1">0.96 (0.23)</td>
                  <td align="left" rowspan="1" colspan="1">0.995 (0.0015)</td>
                  <td align="left" rowspan="1" colspan="1">0.00 (NA)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">04-94XD</td>
                  <td align="left" rowspan="1" colspan="1">6.63</td>
                  <td align="left" rowspan="1" colspan="1">0.12</td>
                  <td align="left" rowspan="1" colspan="1">4.81 (0.22)</td>
                  <td align="left" rowspan="1" colspan="1">0.22 (0.026)</td>
                  <td align="left" rowspan="1" colspan="1">0.999 (0.00030)</td>
                  <td align="left" rowspan="1" colspan="1">0.80 (0.042)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>Mean</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>6.48</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>0.08</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>4.94</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>0.28</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>0.992</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>0.56</bold>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>SD</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>0.54</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>0.043</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>1.18</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>0.33</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>0.0096</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>0.33</bold>
                  </td>
                </tr>
              </tbody>
            </table>
          </alternatives>
          <table-wrap-foot>
            <fn id="nt103">
              <label>1</label>
              <p>This value is not significantly smaller than 0.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>The long-term approximation of the multiscale model provides good fits to the viral load data. The best fits are shown in <xref ref-type="fig" rid="pcbi-1002959-g001">Figure 1</xref> for comparison with the prediction of the biphasic model. Parameter estimates on the basis of the best fits are presented in <xref ref-type="table" rid="pcbi-1002959-t002">Table 2</xref>. The model predicts that danoprevir significantly reduces vRNA production within infected cells, with mean effectiveness <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e254" xlink:type="simple"/></inline-formula>, and has a modest effect in blocking viral assembly or secretion, with mean <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e255" xlink:type="simple"/></inline-formula>. Finding an effect of danoprevir on virion assembly or secretion is consistent with a recent finding that the HCV protease domain is important in late steps in the viral life cycle that involve intracellular assembly of virus <xref ref-type="bibr" rid="pcbi.1002959-Shimakami1">[27]</xref>. With a modest drug efficacy <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e256" xlink:type="simple"/></inline-formula>, the rapid viral decline with slope <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e257" xlink:type="simple"/></inline-formula> occurs over a very short interval and is not visible in the data from these patients (see <xref ref-type="supplementary-material" rid="pcbi.1002959.s001">Text S1</xref>). Because <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e258" xlink:type="simple"/></inline-formula> is close to 1, the viral decline with slope <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e259" xlink:type="simple"/></inline-formula> is visible. Thus, the viral load decline observed during the first two days of treatment mainly reflects a combined effect of danoprevir in reducing viral secretion and in enhancing the degradation of vRNA, with mean <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e260" xlink:type="simple"/></inline-formula> (<xref ref-type="table" rid="pcbi-1002959-t002">Table 2</xref>).</p>
        <p>The viral load decline after day 2 is due to a combined effect of the loss of infected cells, with rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e261" xlink:type="simple"/></inline-formula>, and the exponential reduction in vRNA production, with rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e262" xlink:type="simple"/></inline-formula> (see Eq. 23). We fixed <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e263" xlink:type="simple"/></inline-formula>, which is the mean value estimated during IFN-based therapy <xref ref-type="bibr" rid="pcbi.1002959-Neumann1">[9]</xref>, based on the idea that this value represents the rate of immune-mediated death of infected cells, whereas <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e264" xlink:type="simple"/></inline-formula> represents the rate of “cure” of infected cells due to the loss of replication complexes. Phenomenologically, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e265" xlink:type="simple"/></inline-formula> represents the enhancement in the rate of viral decline after day 2 compared to what was observed during IFN-based therapy. Interestingly, we estimated that the mean of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e266" xlink:type="simple"/></inline-formula> was <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e267" xlink:type="simple"/></inline-formula>, so that the mean long-term viral decline during treatment with danoprevir, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e268" xlink:type="simple"/></inline-formula>, was roughly 3 times more rapid than during IFN therapy. Interestingly, this 3-fold more rapid decline is consistent with the results obtained with the biphasic model where <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e269" xlink:type="simple"/></inline-formula> alone represents the rate of long-term decline. In this case, the mean value of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e270" xlink:type="simple"/></inline-formula> for danoprevir was <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e271" xlink:type="simple"/></inline-formula> (<xref ref-type="table" rid="pcbi-1002959-t001">Table 1</xref>), i.e., 3 times greater than <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e272" xlink:type="simple"/></inline-formula>, the <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e273" xlink:type="simple"/></inline-formula> for IFN.</p>
        <p>The estimate of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e274" xlink:type="simple"/></inline-formula> varies among patients. In three patients (01-94GK, 03-94EA, and 03-94HD), the estimates of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e275" xlink:type="simple"/></inline-formula> were not significantly different from 0. In two patients (03-94EZ and 03-94SN), the estimates of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e276" xlink:type="simple"/></inline-formula> were large (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e277" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e278" xlink:type="simple"/></inline-formula>, respectively). However, only data until day 2 were used in these two patients, due to viral rebound (see <xref ref-type="sec" rid="s2">Materials and Methods</xref>), which inflates the uncertainty in their parameter estimates. In the other two patients (03-94KG and 04-94XD), although no resistance was detected, the viral decline between day 2 and day 14 was modest. In the patients with <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e279" xlink:type="simple"/></inline-formula> not significantly different from 0, either the viral decline was not enhanced by eradication of viral replicative intermediates in infected cells or the default value chosen for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e280" xlink:type="simple"/></inline-formula> was too high, masking any potential effect of intracellular loss of viral replicative intermediates as our model fits can only accurately estimate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e281" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1002959-g003">Figure 3</xref>).</p>
        <p>We also tested the sensitivity of our estimates to changes in the values of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e282" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e283" xlink:type="simple"/></inline-formula>. We refitted the long-term approximation to the viral load data assuming <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e284" xlink:type="simple"/></inline-formula> (10-fold smaller than used in previous fitting) and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e285" xlink:type="simple"/></inline-formula> (10-fold larger than used in previous fitting), i.e., assuming the pre-therapy steady state vRNA (given by <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e286" xlink:type="simple"/></inline-formula>) and viral production (given by <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e287" xlink:type="simple"/></inline-formula>) are 50 and 5-fold higher, respectively, than used in the previous fittings. Although the viral load predictions were similar (not shown), some parameter estimates were different (<xref ref-type="table" rid="pcbi-1002959-t003">Table 3</xref>). Specifically, the estimates of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e288" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e289" xlink:type="simple"/></inline-formula> remained nearly unchanged. The mean estimate of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e290" xlink:type="simple"/></inline-formula>, 0.97, was slightly smaller than the previous mean estimate, 0.992. The mean estimate of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e291" xlink:type="simple"/></inline-formula>, 8.06, was higher than the previous mean estimate, 4.94. One can explain the discrepancy in the estimate of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e292" xlink:type="simple"/></inline-formula> as follows. Because <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e293" xlink:type="simple"/></inline-formula> is modest and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e294" xlink:type="simple"/></inline-formula> is close to 1, the rapid viral decline with slope <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e295" xlink:type="simple"/></inline-formula> is very short and the first visible phase of viral decline is essentially determined by <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e296" xlink:type="simple"/></inline-formula>. Thus, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e297" xlink:type="simple"/></inline-formula> needs to be higher to compensate for the effect of assuming a 10-fold smaller rate of viral secretion, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e298" xlink:type="simple"/></inline-formula>.</p>
        <table-wrap id="pcbi-1002959-t003" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pcbi.1002959.t003</object-id>
          <label>Table 3</label>
          <caption>
            <title>Parameter values with standard errors in parenthesis estimated by fitting the long-term approximation to viral load data and assuming <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e299" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e300" xlink:type="simple"/></inline-formula>, and other fixed parameters as given in <xref ref-type="table" rid="pcbi-1002959-t002">Table 2</xref> caption.</title>
          </caption>
          <alternatives>
            <graphic id="pcbi-1002959-t003-3" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002959.t003" xlink:type="simple"/>
            <table>
              <colgroup span="1">
                <col align="left" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Patient</td>
                  <td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e301" xlink:type="simple"/></inline-formula> (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e302" xlink:type="simple"/></inline-formula>)</td>
                  <td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e303" xlink:type="simple"/></inline-formula> (days)</td>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e304" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e305" xlink:type="simple"/></inline-formula> (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e306" xlink:type="simple"/></inline-formula>)</td>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e307" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <inline-formula>
                      <inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e308" xlink:type="simple"/>
                    </inline-formula>
                  </td>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td align="left" rowspan="1" colspan="1">01-94AB</td>
                  <td align="left" rowspan="1" colspan="1">6.24</td>
                  <td align="left" rowspan="1" colspan="1">0.12</td>
                  <td align="left" rowspan="1" colspan="1">8.27 (0.82)</td>
                  <td align="left" rowspan="1" colspan="1">0.23 (0.056)</td>
                  <td align="left" rowspan="1" colspan="1">0.99 (0.0031)</td>
                  <td align="left" rowspan="1" colspan="1">0.78 (0.060)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">01-94GK</td>
                  <td align="left" rowspan="1" colspan="1">7.24</td>
                  <td align="left" rowspan="1" colspan="1">0.12</td>
                  <td align="left" rowspan="1" colspan="1">5.70 (0.27)</td>
                  <td align="left" rowspan="1" colspan="1">−0.014<xref ref-type="table-fn" rid="nt104">1</xref> (0.026)</td>
                  <td align="left" rowspan="1" colspan="1">0.997 (0.00071)</td>
                  <td align="left" rowspan="1" colspan="1">0.69 (0.051)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">03-94EA</td>
                  <td align="left" rowspan="1" colspan="1">5.79</td>
                  <td align="left" rowspan="1" colspan="1">0.04</td>
                  <td align="left" rowspan="1" colspan="1">8.11 (2.02)</td>
                  <td align="left" rowspan="1" colspan="1">0.00033 (0.047)</td>
                  <td align="left" rowspan="1" colspan="1">0.97 (0.012)</td>
                  <td align="left" rowspan="1" colspan="1">0.71 (0.18)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">03-94EZ</td>
                  <td align="left" rowspan="1" colspan="1">6.56</td>
                  <td align="left" rowspan="1" colspan="1">0.12</td>
                  <td align="left" rowspan="1" colspan="1">12.67 (1.82)</td>
                  <td align="left" rowspan="1" colspan="1">0.55 (0.32)</td>
                  <td align="left" rowspan="1" colspan="1">0.98 (0.0088)</td>
                  <td align="left" rowspan="1" colspan="1">0.13 (0.35)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">03-94HD</td>
                  <td align="left" rowspan="1" colspan="1">6.72</td>
                  <td align="left" rowspan="1" colspan="1">0.04</td>
                  <td align="left" rowspan="1" colspan="1">4.63 (1.14)</td>
                  <td align="left" rowspan="1" colspan="1">0.095 (0.048)</td>
                  <td align="left" rowspan="1" colspan="1">0.96 (0.019)</td>
                  <td align="left" rowspan="1" colspan="1">0.92 (0.037)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">03-94KG</td>
                  <td align="left" rowspan="1" colspan="1">6.98</td>
                  <td align="left" rowspan="1" colspan="1">0.04</td>
                  <td align="left" rowspan="1" colspan="1">7.49 (2.57)</td>
                  <td align="left" rowspan="1" colspan="1">0.19 (0.036)</td>
                  <td align="left" rowspan="1" colspan="1">0.85 (0.060)</td>
                  <td align="left" rowspan="1" colspan="1">0.55 (0.25)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">03-94SN</td>
                  <td align="left" rowspan="1" colspan="1">5.74</td>
                  <td align="left" rowspan="1" colspan="1">0.04</td>
                  <td align="left" rowspan="1" colspan="1">11.45 (0.72)</td>
                  <td align="left" rowspan="1" colspan="1">0.96 (0.23)</td>
                  <td align="left" rowspan="1" colspan="1">0.98 (0.0072)</td>
                  <td align="left" rowspan="1" colspan="1">0.00 (NA)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">04-94XD</td>
                  <td align="left" rowspan="1" colspan="1">6.63</td>
                  <td align="left" rowspan="1" colspan="1">0.12</td>
                  <td align="left" rowspan="1" colspan="1">6.21 (0.37)</td>
                  <td align="left" rowspan="1" colspan="1">0.22 (0.026)</td>
                  <td align="left" rowspan="1" colspan="1">0.994 (0.0015)</td>
                  <td align="left" rowspan="1" colspan="1">0.81 (0.042)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>Mean</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>6.48</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>0.08</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>8.06</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>0.28</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>0.97</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>0.57</bold>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>SD</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>0.54</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>0.043</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>2.77</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>0.32</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>0.048</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>0.33</bold>
                  </td>
                </tr>
              </tbody>
            </table>
          </alternatives>
          <table-wrap-foot>
            <fn id="nt104">
              <label>1</label>
              <p>This value is not significantly smaller than 0.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
    </sec>
    <sec id="s4">
      <title>Discussion</title>
      <p>Direct-acting antiviral agents that interfere with various intracellular molecular processes in the HCV life cycle are revolutionizing therapy for patients chronically infected with HCV <xref ref-type="bibr" rid="pcbi.1002959-Fusco1">[28]</xref>, <xref ref-type="bibr" rid="pcbi.1002959-Hoofnagle1">[29]</xref>. Two protease inhibitors, telaprevir and boceprevir have been approved by the US Food and Drug Administration to treat HCV infection when used in combination with PEG-IFN/RBV. They can effectively block the NS3-4A protease-dependent cleavage of the HCV polyprotein, which is essential for viral replication. The addition of either of them to therapy with PEG-IFN/RBV has significantly increased the rate of SVR <xref ref-type="bibr" rid="pcbi.1002959-Poordad1">[4]</xref>–<xref ref-type="bibr" rid="pcbi.1002959-Bacon1">[8]</xref>. These compounds, viewed as the first generation of PIs, have several shortcomings: side effects including serious rash for telaprevir, the necessity to be taken three times a day, and limited effectiveness for non-genotype 1 patients. Moreover, these drugs have a poor resistance profile and drug resistant virus rapidly emerges when these PIs are used as monotherapy <xref ref-type="bibr" rid="pcbi.1002959-Rong3">[30]</xref>. Although still in clinical development there are good expectations that the second generation of PIs will overcome some of these shortcomings (see reviews in <xref ref-type="bibr" rid="pcbi.1002959-Ciesek1">[31]</xref>, <xref ref-type="bibr" rid="pcbi.1002959-Schaefer1">[32]</xref>). Danoprevir is one such compound and it has shown potent antiviral activities <italic>in vitro</italic>, in the HCV replicon model, as well as in treatment-naive and treatment-experienced patients in combination with PEG-IFN/RBV <xref ref-type="bibr" rid="pcbi.1002959-Forestier1">[15]</xref>, <xref ref-type="bibr" rid="pcbi.1002959-Gane1">[33]</xref>, <xref ref-type="bibr" rid="pcbi.1002959-Forestier2">[34]</xref> or mericitabine, an HCV polymerase inhibitor <xref ref-type="bibr" rid="pcbi.1002959-Gane2">[35]</xref>. Despite robust antiviral responses of danoprevir and other DAAs, their mechanisms of action and <italic>in vivo</italic> antiviral efficacy remain unclear.</p>
      <p>The standard biphasic viral dynamic model is commonly used to study HCV dynamics in patients on therapy and to estimate the values of parameters such as the virion half-life, the productively infected cell loss rate, and the effectiveness of therapy in blocking viral production. By fitting this model to the viral load decline in HCV patients receiving high daily doses of IFN, Neumann et al. <xref ref-type="bibr" rid="pcbi.1002959-Neumann1">[9]</xref> estimated that the viral clearance rate, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e309" xlink:type="simple"/></inline-formula>, was about <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e310" xlink:type="simple"/></inline-formula>, corresponding to a serum half-life, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e311" xlink:type="simple"/></inline-formula>, of 2.7 hours. The model was also used to fit the viral load data in patients treated with DAAs <xref ref-type="bibr" rid="pcbi.1002959-Adiwijaya1">[18]</xref>. In patients receiving the HCV NS5A inhibitor daclatasvir, the estimate of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e312" xlink:type="simple"/></inline-formula> was <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e313" xlink:type="simple"/></inline-formula>, corresponding to a <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e314" xlink:type="simple"/></inline-formula> of 45 minutes <xref ref-type="bibr" rid="pcbi.1002959-Guedj3">[14]</xref>. Using this model to fit viral load decline from eight patients during two weeks of danoprevir monotherapy, we estimated a mean <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e315" xlink:type="simple"/></inline-formula> of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e316" xlink:type="simple"/></inline-formula> corresponding to a <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e317" xlink:type="simple"/></inline-formula> of 1.6 hours. Because the viral clearance rate is a physiological parameter, it should not depend on the specific antiviral agent used in a study. An obvious discrepancy in the estimates of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e318" xlink:type="simple"/></inline-formula> suggests that the biphasic model, which does not include the dynamics of intracellular viral replication within infected cells, may not be optimal for analyzing data in patients treated with DAAs.</p>
      <p>In this paper, we introduced a more sophisticated multiscale model including intracellular viral replication that can be used to study the viral kinetic changes in patients treated with DAAs. Unlike the standard biphasic model that only considers the effect of treatment in reducing the average viral production/release per infected cell <xref ref-type="bibr" rid="pcbi.1002959-Neumann1">[9]</xref>, the multiscale model allows one to estimate three specific effects of the therapy, namely inhibition of vRNA production, enhancement of vRNA degradation, and inhibition of viral assembly and/or secretion.</p>
      <p>Analysis of the multiscale model (<xref ref-type="supplementary-material" rid="pcbi.1002959.s001">Text S1</xref> and <xref ref-type="fig" rid="pcbi-1002959-g003">Figure 3</xref>) shows that the first phase of viral decline occurring during the first 6 to 8 hrs after therapy initiation and representing virion clearance in serum can be observed only if therapy substantially blocks viral assembly/secretion. If therapy can also efficiently inhibit intracellular viral production, there is a visible second-phase viral decline, mainly reflecting the loss of material available for producing new virions. This new understanding of the origin of viral decline can be used to explore the mechanisms of action of DAAs. For example, by fitting the long-term approximation of this model to the first two days of viral load data in patients treated with the NS5A inhibitor daclatasvir, it was predicted that daclatasvir efficiently blocks both intracellular viral RNA production and virion assembly/secretion <xref ref-type="bibr" rid="pcbi.1002959-Guedj3">[14]</xref>. Thus, during therapy with daclatasvir, the first-phase viral decline reveals the information on the virion clearance rate in serum and the mean half-life of HCV RNA in serum was estimated to be about 45 minutes. This estimate is approximately 4 times shorter than previous estimates made during IFN-based therapy <xref ref-type="bibr" rid="pcbi.1002959-Neumann1">[9]</xref>, <xref ref-type="bibr" rid="pcbi.1002959-Snoeck1">[36]</xref>. However, it agrees with the estimates made during the anhepatic phase and immediately after graft reperfusion in the majority of patients who underwent liver transplantation <xref ref-type="bibr" rid="pcbi.1002959-Powers1">[37]</xref>, <xref ref-type="bibr" rid="pcbi.1002959-Dahari4">[38]</xref>. Also, the estimated virion half-life of 45 minutes can be obtained without the use of the multiscale model by simply estimating via linear regression the rate of viral decline plotted in Figure 4 of ref. <xref ref-type="bibr" rid="pcbi.1002959-Gao1">[39]</xref>.</p>
      <p>When therapy only moderately blocks viral assembly/secretion, as shown with danoprevir (<xref ref-type="table" rid="pcbi-1002959-t002">Table 2</xref>) or IFN <xref ref-type="bibr" rid="pcbi.1002959-Guedj3">[14]</xref>, there is continued packing of vRNAs, made in infected cells before therapy began, and continued release of virions during therapy, which masks the intrinsic virion clearance rate in serum. In this case, the rapid exponential decline of virus reflecting clearance at rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e319" xlink:type="simple"/></inline-formula> is not observed, and the first visible phase of viral decline mainly reflects the loss rate of vRNA within an infected cell. Here we estimate that danoprevir when given as 200 mg three times a day leads to an enhancement of the vRNA degradation rate by a mean factor of approximately 5. When using the standard biphasic model rather than the multiscale model, this early viral decline phase was attributed to a high viral clearance rate, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e320" xlink:type="simple"/></inline-formula>, of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e321" xlink:type="simple"/></inline-formula>. This is substantially higher than the typical value of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e322" xlink:type="simple"/></inline-formula> estimated during IFN-based therapy <xref ref-type="bibr" rid="pcbi.1002959-Neumann1">[9]</xref>. As our new model indicates that this phase mainly reflects vRNA degradation rather than viral clearance, these results suggest that danoprevir induces a more profound enhancement of vRNA degradation than IFN. Likewise, using the standard biphasic model to fit the viral decline in patients treated with 1250 mg telaprevir given twice a day, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e323" xlink:type="simple"/></inline-formula> was estimated to be equal to <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e324" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1002959-Adiwijaya1">[18]</xref>. However, using the new modeling approach, we showed elsewhere that telaprevir, like danoprevir, enhances the vRNA rate of degradation with mean <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e325" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1002959-Guedj3">[14]</xref>. Direct comparisons of the effects of telprevir and danoprevir should not be made as these results come from different studies, with different patient populations and different doses of drug, but nonetheless these studies suggest both drugs behave similarly.</p>
      <p>Why danoprevir and telaprevir enhance the intracellular viral RNA degradation rate remains unclear. It might result from the restoration of cellular antiviral capabilities <xref ref-type="bibr" rid="pcbi.1002959-Dustin1">[40]</xref>. Type I IFNs and other inflammatory cytokines can be induced in infected cells that recognize vRNA <xref ref-type="bibr" rid="pcbi.1002959-Akira1">[41]</xref>. However, the HCV NS3-4A protease interferes with this pathway by cleaving the Toll-like receptor 3 adaptor protein TRIF <xref ref-type="bibr" rid="pcbi.1002959-Li1">[42]</xref>, and blocking the activation of IFN regulatory factor 3 (IRF-3), a key cellular antiviral signaling molecule <xref ref-type="bibr" rid="pcbi.1002959-Foy1">[43]</xref>. Thus, inhibition of the NS3-4A protease may simultaneously block viral replication and restore a cellular antiviral response that might promote intracellular viral RNA degradation. One candidate pathway involves ADAR1, an adenosine deaminase that acts on double-stranded RNA. This enzyme is induced by type I IFN, and it specifically eliminates HCV RNA by adenosine to inosine editing <xref ref-type="bibr" rid="pcbi.1002959-Taylor1">[44]</xref>.</p>
      <p>Approximately two days after the start of danoprevir therapy, a subsequent and persistent phase of viral decline was observed that was about three times faster than typically found during IFN-based therapy <xref ref-type="bibr" rid="pcbi.1002959-Neumann1">[9]</xref>. Using the standard biphasic model, one would attribute this enhanced phase of viral decline to an elevated loss rate of infected cells. However, it seems unlikely that this elevated loss rate is due to cell death as no increase in the level of alanine aminotransferase (ALT), an enzyme released from damaged or dead hepatocytes, was observed in the 8 patients treated with danoprevir. We hypothesized that the elevated rate of viral decline is due to a continuous reduction in vRNA production, with the rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e326" xlink:type="simple"/></inline-formula>. This assumption seems reasonable because HCV negative strand RNAs (or equivalently replication complexes) degrade <xref ref-type="bibr" rid="pcbi.1002959-Dahari2">[20]</xref> and are not replaced or inefficiently replaced if RNA replication is largely inhibited by effective therapy. A more complete model would include the dynamics of formation and elimination of replication complexes, as done in <xref ref-type="bibr" rid="pcbi.1002959-Guedj2">[13]</xref>. However, we would then have additional intracellular equations and need to determine more unknown parameters. Assuming an exponential decay in the vRNA production rate (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e327" xlink:type="simple"/></inline-formula>) is the simplest way to capture this effect. The same approach was used to study the dynamics of genotype 1b subgenomic replicon RNA under treatment with <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e328" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1002959-Dahari1">[19]</xref>.</p>
      <p>The long-term approximation in which all new infections are neglected agrees well with the prediction of the full model in the context of an effective therapy. However, the approximation cannot be applied to the full data set from three patients (01-94AB, 03-94EZ, and 03-94SN) in which viral rebound was observed during the 2-week monotherapy. Virologic escape during danoprevir monotherapy was reported to be HCV subtype dependent and mainly due to the emergence of drug resistance associated with the substitution R155K <xref ref-type="bibr" rid="pcbi.1002959-Lim1">[45]</xref>. Further, even in patients with no observed escape resistant variants may be present and slowing viral decline rates. This is probably a common feature of all drugs with a low genetic barrier to resistance. Thus, the current model, assuming no drug resistance, may be underestimating the effect of danoprevir. Extending the model to include two strains <xref ref-type="bibr" rid="pcbi.1002959-Rong3">[30]</xref> or multiple strains <xref ref-type="bibr" rid="pcbi.1002959-Adiwijaya2">[46]</xref>–<xref ref-type="bibr" rid="pcbi.1002959-Rong4">[48]</xref> is one method to study the evolution of drug resistance, estimate the <italic>in vivo</italic> fitness of drug-resistant HCV variants, and quantify the effects of resistant variants on the kinetics of HCV RNA decline. In addition, the current model assumes constant drug efficacy. Pharmacokinetic/pharmacodynamic models could be included to describe the time-varying treatment effectiveness <xref ref-type="bibr" rid="pcbi.1002959-Powers2">[49]</xref>–<xref ref-type="bibr" rid="pcbi.1002959-Dahari5">[51]</xref>. However, more data are needed for parameter estimation.</p>
      <p>In the context of potent therapy leading to a continuous viral decline, mathematical analysis of the standard biphasic model has shown that an additional effect of drug in blocking infection and/or viral entry has no or very limited effect on the kinetics of viral decline <xref ref-type="bibr" rid="pcbi.1002959-Neumann1">[9]</xref>, <xref ref-type="bibr" rid="pcbi.1002959-Guedj4">[52]</xref>. This is the reason why such an effect was not studied here. However, in the context of emerging drug resistant virus or new cell infection, the ability of a drug to block viral entry should be considered as it could have a significant effect in delaying or preventing a viral breakthrough by preventing the ability of resistant virus to infect and propagate in new cells.</p>
      <p>Another limitation of our model is that we have assumed that <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e329" xlink:type="simple"/></inline-formula> is constant and not influenced by danoprevir. As far as we know there is no evidence that a protease inhibitor such as danoprevir will influence virion clearance. However, if danoprevir did increase <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e330" xlink:type="simple"/></inline-formula> from about the <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e331" xlink:type="simple"/></inline-formula> seen with IFN to the <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e332" xlink:type="simple"/></inline-formula> estimated here using the standard model, i.e. by a factor of 2, then the viral load would decline by a factor of 2 during the first phase and not by the more than 2 orders of magnitude observed. Thus, any increase of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e333" xlink:type="simple"/></inline-formula> would not explain the profound drop in viral load seen during the first phase. Nonetheless, we cannot rule out the possibility that <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1002959.e334" xlink:type="simple"/></inline-formula> is increased along with the other effects we predicted, such as the block in HCV RNA replication.</p>
      <p>In summary, we employed a multiscale model that includes both intracellular RNA replication and extracellular infection dynamics to study the viral load change in HCV patients treated with DAAs. We determined the biological parameters that contribute to different phases of viral decline after initiation of therapy. Applying the model to viral load data from patients treated with a new HCV protease inhibitor, danoprevir, suggests that danoprevir significantly blocks intracellular viral production and enhances viral degradation, while it moderately inhibits viral assembly/secretion. The multiscale model provides a theoretical framework that can be used to explore the mechanisms of action of other DAAs and thus should be useful in furthering drug development for HCV and for optimizing antiviral therapy.</p>
    </sec>
    <sec id="s5">
      <title>Supporting Information</title>
      <supplementary-material id="pcbi.1002959.s001" mimetype="application/pdf" xlink:href="info:doi/10.1371/journal.pcbi.1002959.s001" position="float" xlink:type="simple">
        <label>Text S1</label>
        <caption>
          <p>Model analysis and approximation.</p>
          <p>(PDF)</p>
        </caption>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="pcbi.1002959-World1">
        <label>1</label>
        <mixed-citation publication-type="other" xlink:type="simple">World Health Organization. Hepatitis C. Fact sheet No. 164. Revised June 2011. <ext-link ext-link-type="uri" xlink:href="http://www.who.int/mediacentre/factsheets/fs164/en/index.html" xlink:type="simple">http://www.who.int/mediacentre/factsheets/fs164/en/index.html</ext-link>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Cardoso1">
        <label>2</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cardoso</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Moucari</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Figueiredo-Mendes</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Ripault</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Giuily</surname><given-names>N</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis</article-title>. <source>J Hepatol</source> <volume>52</volume>: <fpage>652</fpage>–<lpage>7</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Awad1">
        <label>3</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Awad</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Thorlund</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Hauser</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Stimac</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Mabrouk</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials</article-title>. <source>Hepatology</source> <volume>51</volume>: <fpage>1176</fpage>–<lpage>84</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Poordad1">
        <label>4</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Poordad</surname><given-names>F</given-names></name>, <name name-style="western"><surname>McCone</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Bacon</surname><given-names>BR</given-names></name>, <name name-style="western"><surname>Bruno</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Manns</surname><given-names>MP</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Boceprevir for untreated chronic HCV genotype 1 infection</article-title>. <source>N Engl J Med</source> <volume>364</volume>: <fpage>1195</fpage>–<lpage>206</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Hezode1">
        <label>5</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hezode</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Forestier</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Dusheiko</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Ferenci</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Pol</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Telaprevir and peginterferon with or without ribavirin for chronic HCV infection</article-title>. <source>N Engl J Med</source> <volume>360</volume>: <fpage>1839</fpage>–<lpage>50</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-McHutchison1">
        <label>6</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>McHutchison</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Everson</surname><given-names>GT</given-names></name>, <name name-style="western"><surname>Gordon</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Jacobson</surname><given-names>IM</given-names></name>, <name name-style="western"><surname>Sulkowski</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection</article-title>. <source>N Engl J Med</source> <volume>360</volume>: <fpage>1827</fpage>–<lpage>38</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Sherman1">
        <label>7</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sherman</surname><given-names>KE</given-names></name>, <name name-style="western"><surname>Flamm</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Afdhal</surname><given-names>NH</given-names></name>, <name name-style="western"><surname>Nelson</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>Sulkowski</surname><given-names>MS</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Responseguided telaprevir combination treatment for hepatitis C virus infection</article-title>. <source>N Engl J Med</source> <volume>365</volume>: <fpage>1014</fpage>–<lpage>24</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Bacon1">
        <label>8</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bacon</surname><given-names>BR</given-names></name>, <name name-style="western"><surname>Gordon</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Lawitz</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Marcellin</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Vierling</surname><given-names>JM</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Boceprevir for previously treated chronic HCV genotype 1 infection</article-title>. <source>N Engl J Med</source> <volume>364</volume>: <fpage>1207</fpage>–<lpage>17</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Neumann1">
        <label>9</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Neumann</surname><given-names>AU</given-names></name>, <name name-style="western"><surname>Lam</surname><given-names>NP</given-names></name>, <name name-style="western"><surname>Dahari</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Gretch</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>Wiley</surname><given-names>TE</given-names></name>, <etal>et al</etal>. (<year>1998</year>) <article-title>Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy</article-title>. <source>Science</source> <volume>282</volume>: <fpage>103</fpage>–<lpage>7</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Dixit1">
        <label>10</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dixit</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Layden-Almer</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Layden</surname><given-names>TJ</given-names></name>, <name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name> (<year>2004</year>) <article-title>Modelling how ribavirin improves interferon response rates in hepatitis C virus infection</article-title>. <source>Nature</source> <volume>432</volume>: <fpage>922</fpage>–<lpage>4</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Guedj1">
        <label>11</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Guedj</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Rong</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Dahari</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name> (<year>2010</year>) <article-title>A perspective on modelling hepatitis C virus infection</article-title>. <source>J Viral Hepat</source> <volume>17</volume>: <fpage>825</fpage>–<lpage>33</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Rong1">
        <label>12</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rong</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name> (<year>2010</year>) <article-title>Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling</article-title>. <source>Crit Rev Immunol</source> <volume>30</volume>: <fpage>131</fpage>–<lpage>48</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Guedj2">
        <label>13</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Guedj</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Neumann</surname><given-names>AU</given-names></name> (<year>2010</year>) <article-title>Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics</article-title>. <source>J Theor Biol</source> <volume>267</volume>: <fpage>330</fpage>–<lpage>40</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Guedj3">
        <label>14</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Guedj</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Dahari</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Rong</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Sansone</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Nettles</surname><given-names>RE</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life</article-title>. <source>Proc Natl Acad Sci USA</source> <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.1203110110," xlink:type="simple">10.1073/pnas.1203110110,</ext-link></comment></mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Forestier1">
        <label>15</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Forestier</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Larrey</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Guyader</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Marcellin</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Rouzier</surname><given-names>R</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study</article-title>. <source>J Hepatol</source> <volume>54</volume>: <fpage>1130</fpage>–<lpage>6</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Neumann2">
        <label>16</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Neumann</surname><given-names>AU</given-names></name>, <name name-style="western"><surname>Lam</surname><given-names>NP</given-names></name>, <name name-style="western"><surname>Dahari</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Davidian</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wiley</surname><given-names>TE</given-names></name>, <etal>et al</etal>. (<year>2000</year>) <article-title>Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus</article-title>. <source>J Infect Dis</source> <volume>182</volume>: <fpage>28</fpage>–<lpage>35</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Sherman2">
        <label>17</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sherman</surname><given-names>KE</given-names></name>, <name name-style="western"><surname>Shire</surname><given-names>NJ</given-names></name>, <name name-style="western"><surname>Rouster</surname><given-names>SD</given-names></name>, <name name-style="western"><surname>Peters</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>James Koziel</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients</article-title>. <source>Gastroenterology</source> <volume>128</volume>: <fpage>313</fpage>–<lpage>27</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Adiwijaya1">
        <label>18</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Adiwijaya</surname><given-names>BS</given-names></name>, <name name-style="western"><surname>Hare</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Caron</surname><given-names>PR</given-names></name>, <name name-style="western"><surname>Randle</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Neumann</surname><given-names>AU</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Rapid decrease of wild-type hepatitis C virus on telaprevir treatment</article-title>. <source>Antivir Ther</source> <volume>14</volume>: <fpage>591</fpage>–<lpage>5</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Dahari1">
        <label>19</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dahari</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Sainz</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Uprichard</surname><given-names>SL</given-names></name> (<year>2009</year>) <article-title>Modeling subgenomic hepatitis C virus RNA kinetics during treatment with alpha interferon</article-title>. <source>J Virol</source> <volume>83</volume>: <fpage>6383</fpage>–<lpage>90</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Dahari2">
        <label>20</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dahari</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Ribeiro</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Rice</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name> (<year>2007</year>) <article-title>Mathematical modeling of subgenomic hepatitis C virus replication in Huh-7 cells</article-title>. <source>J Virol</source> <volume>81</volume>: <fpage>750</fpage>–<lpage>60</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Marquardt1">
        <label>21</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Marquardt</surname><given-names>DW</given-names></name> (<year>1963</year>) <article-title>An algorithm for least-squares estimation of nonlinear parameters</article-title>. <source>J Soc Indust Appl Math</source> <volume>11</volume>: <fpage>431</fpage>–<lpage>41</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Lin1">
        <label>22</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lin</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kwong</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>C</given-names></name> (<year>2004</year>) <article-title>Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells</article-title>. <source>Antimicrob Agents Chemother</source> <volume>48</volume>: <fpage>4784</fpage>–<lpage>92</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Blight1">
        <label>23</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Blight</surname><given-names>KJ</given-names></name>, <name name-style="western"><surname>McKeating</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Rice</surname><given-names>CM</given-names></name> (<year>2002</year>) <article-title>Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication</article-title>. <source>J Virol</source> <volume>76</volume>: <fpage>13001</fpage>–<lpage>14</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Nelson1">
        <label>24</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nelson</surname><given-names>PW</given-names></name>, <name name-style="western"><surname>Gilchrist</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Coombs</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Hyman</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name> (<year>2004</year>) <article-title>An age-structured model of hiv infection that allows for variations in the production rate of viral particles and the death rate of productively infected cells</article-title>. <source>Math Biosci Eng</source> <volume>1</volume>: <fpage>267</fpage>–<lpage>88</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Rong2">
        <label>25</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rong</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Feng</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name> (<year>2007</year>) <article-title>Mathematical analysis of age-structured HIV-1 dynamics with combination antiretroviral therapy</article-title>. <source>SIAM J Appl Math</source> <volume>67</volume>: <fpage>731</fpage>–<lpage>56</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Dahari3">
        <label>26</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dahari</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Barretto</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Sainz</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>Guedj</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Modeling interferonalpha mediated inhibition kinetics of intracellular and extracellular HCV RNA during HCV infection in vitro</article-title>. <source>J Hepatol</source> <volume>54</volume>: <fpage>S312</fpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Shimakami1">
        <label>27</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shimakami</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Welsch</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Yamane</surname><given-names>D</given-names></name>, <name name-style="western"><surname>McGivern</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>Yi</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Protease inhibitorresistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus</article-title>. <source>Gastroenterology</source> <volume>140</volume>: <fpage>667</fpage>–<lpage>75</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Fusco1">
        <label>28</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fusco</surname><given-names>DN</given-names></name>, <name name-style="western"><surname>Chung</surname><given-names>RT</given-names></name> (<year>2012</year>) <article-title>Novel therapies for hepatitis C: insights from the structure of the virus</article-title>. <source>Annu Rev Med</source> <volume>63</volume>: <fpage>373</fpage>–<lpage>87</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Hoofnagle1">
        <label>29</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hoofnagle</surname><given-names>JH</given-names></name> (<year>2009</year>) <article-title>A step forward in therapy for hepatitis C</article-title>. <source>N Engl J Med</source> <volume>360</volume>: <fpage>1899</fpage>–<lpage>901</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Rong3">
        <label>30</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rong</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Dahari</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Ribeiro</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name> (<year>2010</year>) <article-title>Rapid emergence of protease inhibitor resistance in hepatitis C virus</article-title>. <source>Sci Transl Med</source> <volume>2</volume>: <fpage>30ra32</fpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Ciesek1">
        <label>31</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ciesek</surname><given-names>S</given-names></name>, <name name-style="western"><surname>von Hahn</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Manns</surname><given-names>MP</given-names></name> (<year>2011</year>) <article-title>Second-wave protease inhibitors: choosing an heir</article-title>. <source>Clin Liver Dis</source> <volume>15</volume>: <fpage>597</fpage>–<lpage>609</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Schaefer1">
        <label>32</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schaefer</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>Chung</surname><given-names>RT</given-names></name> (<year>2012</year>) <article-title>Anti-hepatitis C virus drugs in development</article-title>. <source>Gastroenterology</source> <volume>142</volume>: <fpage>1340</fpage>–<lpage>1350 e1</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Gane1">
        <label>33</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gane</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Rouzier</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Stedman</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Wiercinska-Drapalo</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Horban</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN alpha-2a/RBV in hepatitis C patients</article-title>. <source>J Hepatol</source> <volume>55</volume>: <fpage>972</fpage>–<lpage>9</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Forestier2">
        <label>34</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Forestier</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Larrey</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Marcellin</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Guyader</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Patat</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon alpha-2a and ribavirin in patients with hepatitis C</article-title>. <source>J Infect Dis</source> <volume>204</volume>: <fpage>601</fpage>–<lpage>8</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Gane2">
        <label>35</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gane</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Roberts</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Stedman</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Angus</surname><given-names>PW</given-names></name>, <name name-style="western"><surname>Ritchie</surname><given-names>B</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, doseescalation trial</article-title>. <source>Lancet</source> <volume>376</volume>: <fpage>1467</fpage>–<lpage>75</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Snoeck1">
        <label>36</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Snoeck</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Chanu</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Lavielle</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Jacqmin</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Jonsson</surname><given-names>EN</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>A comprehensive hepatitis C viral kinetic model explaining cure</article-title>. <source>Clin Pharmacol Ther</source> <volume>87</volume>: <fpage>706</fpage>–<lpage>13</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Powers1">
        <label>37</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Powers</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Ribeiro</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Patel</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Pianko</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Nyberg</surname><given-names>L</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>Kinetics of hepatitis C virus reinfection after liver transplantation</article-title>. <source>Liver Transpl</source> <volume>12</volume>: <fpage>207</fpage>–<lpage>16</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Dahari4">
        <label>38</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dahari</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Feliu</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Garcia-Retortillo</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Forns</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Neumann</surname><given-names>AU</given-names></name> (<year>2005</year>) <article-title>Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation</article-title>. <source>J Hepatol</source> <volume>42</volume>: <fpage>491</fpage>–<lpage>8</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Gao1">
        <label>39</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gao</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Nettles</surname><given-names>RE</given-names></name>, <name name-style="western"><surname>Belema</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Snyder</surname><given-names>LB</given-names></name>, <name name-style="western"><surname>Nguyen</surname><given-names>VN</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect</article-title>. <source>Nature</source> <volume>465</volume>: <fpage>96</fpage>–<lpage>100</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Dustin1">
        <label>40</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dustin</surname><given-names>LB</given-names></name>, <name name-style="western"><surname>Rice</surname><given-names>CM</given-names></name> (<year>2007</year>) <article-title>Flying under the radar: the immunobiology of hepatitis C</article-title>. <source>Annu Rev Immunol</source> <volume>25</volume>: <fpage>71</fpage>–<lpage>99</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Akira1">
        <label>41</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Akira</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Uematsu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Takeuchi</surname><given-names>O</given-names></name> (<year>2006</year>) <article-title>Pathogen recognition and innate immunity</article-title>. <source>Cell</source> <volume>124</volume>: <fpage>783</fpage>–<lpage>801</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Li1">
        <label>42</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Foy</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Ferreon</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Nakamura</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ferreon</surname><given-names>AC</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF</article-title>. <source>Proc Natl Acad Sci USA</source> <volume>102</volume>: <fpage>2992</fpage>–<lpage>7</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Foy1">
        <label>43</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Foy</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Sumpter J</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ikeda</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2003</year>) <article-title>Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease</article-title>. <source>Science</source> <volume>300</volume>: <fpage>1145</fpage>–<lpage>8</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Taylor1">
        <label>44</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Taylor</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>Puig</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Darnell</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Mihalik</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Feinstone</surname><given-names>SM</given-names></name> (<year>2005</year>) <article-title>New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1</article-title>. <source>J Virol</source> <volume>79</volume>: <fpage>6291</fpage>–<lpage>8</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Lim1">
        <label>45</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lim</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Qin</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Susser</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Nicholas</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Lange</surname><given-names>C</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution</article-title>. <source>Antimicrob Agents Chemother</source> <volume>56</volume>: <fpage>271</fpage>–<lpage>9</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Adiwijaya2">
        <label>46</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Adiwijaya</surname><given-names>BS</given-names></name>, <name name-style="western"><surname>Herrmann</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Hare</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Kieffer</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>C</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants</article-title>. <source>PLoS Comput Biol</source> <volume>6</volume>: <fpage>e1000745</fpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Adiwijaya3">
        <label>47</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Adiwijaya</surname><given-names>BS</given-names></name>, <name name-style="western"><surname>Kieffer</surname><given-names>TL</given-names></name>, <name name-style="western"><surname>Henshaw</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Eisenhauer</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kimko</surname><given-names>H</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection</article-title>. <source>PLoS Comput Biol</source> <volume>8</volume>: <fpage>e1002339</fpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Rong4">
        <label>48</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rong</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Ribeiro</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name> (<year>2012</year>) <article-title>Modeling quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitor</article-title>. <source>Bull Math Biol</source> <volume>74</volume>: <fpage>1789</fpage>–<lpage>817</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Powers2">
        <label>49</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Powers</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Dixit</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Ribeiro</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Golia</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Talal</surname><given-names>AH</given-names></name>, <etal>et al</etal>. (<year>2003</year>) <article-title>Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b</article-title>. <source>Semin Liver Dis</source> <volume>23</volume> <supplement>Suppl 1</supplement>: <fpage>13</fpage>–<lpage>8</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Talal1">
        <label>50</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Talal</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Ribeiro</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Powers</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Grace</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Cullen</surname><given-names>C</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders</article-title>. <source>Hepatology</source> <volume>43</volume>: <fpage>943</fpage>–<lpage>53</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Dahari5">
        <label>51</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dahari</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Affonso de Araujo</surname><given-names>ES</given-names></name>, <name name-style="western"><surname>Haagmans</surname><given-names>BL</given-names></name>, <name name-style="western"><surname>Layden</surname><given-names>TJ</given-names></name>, <name name-style="western"><surname>Cotler</surname><given-names>SJ</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: Implications for treatment outcomes</article-title>. <source>J Hepatol</source> <volume>53</volume>: <fpage>460</fpage>–<lpage>7</lpage>.</mixed-citation>
      </ref>
      <ref id="pcbi.1002959-Guedj4">
        <label>52</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Guedj</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Dahari</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Pohl</surname><given-names>RT</given-names></name>, <name name-style="western"><surname>Ferenci</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name> (<year>2012</year>) <article-title>Understanding silibinin's modes of action against HCV using viral kinetic modeling</article-title>. <source>J Hepatol</source> <volume>56</volume>: <fpage>1019</fpage>–<lpage>24</lpage>.</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>